I-MED Pharma USA Gains Exclusive Distribution Rights for ESW Vision’s E>Eye and Tearcheck in the United States

I-MED Pharma has announced the expansion of their strategic partnership with ESW Vision in France to be their exclusive distributor in the United States. Through I-MED Pharma USA, two dry eye devices will be available directly to all eye care professionals across the country.

E>Eye is the first and only CE certified medical device using patented IRPL technology developed specifically for the treatment of dry eye disease caused by meibomian gland dysfunction (MGD), the leading cause of evaporative dry eye.

This new type of polychromatic pulsed light produces calibrated and homogeneously sequenced “cold light” pulses, which safely stimulate the meibomian glands to resume secretions, restoring the lacrymal film and improving symptoms associated with ocular dryness.

Tearcheck is a dry eye diagnostic and analyzer tool that performs nine exams in under 10 minutes. The innovative technology and unique usability of this diagnostic device creates a new standard for dry eye analysis.

“We are proud to be building on the worldwide success of these two innovative and leading-edge dry eye devices. With thousands of units installed worldwide, this technology has become globally regarded as the gold standard," Philipp Binder, President and Chief Operations Officer of I-MED Pharma, said in a company news release. "These devices have been quickly recognized as the number one technology in Canada by eye care professionals, and we are excited to bring this innovation to the US market. Our strategic collaboration with ESW Vision over the last 3 years has pushed us forward in our mission to bring complete relief to dry eye and ocular surface disease patients worldwide.”